"When you have a controlled substance problem, the DEA has to be involved in fixing it," says Ruth Hughes, CEO at Children and Adults with Attention Deficit/Hyperactivity Disorder. Drugs like Adderall and Ritalin, which have controlled-substance APIs among the 400 basic substances and derivatives regulated by the U.S. Drug Enforcement Agency, present an additional hurdle when it comes to resolving shortages. "It is not sufficient to say it is an industry problem. We need to figure out how to build more flexibility into the system." Story